Good news! Lyme Disease Vaccine Shows Promise in Clinical Trial
Good news! Valneva, a French biotech company, has reported positive results from their Lyme Disease vaccine’s Phase 2 Trials. The vaccine has produced an immune response from participants of all age groups and was particularly effective in older adults.
The study was performed on 572 adults aged 18-65 and was determined to be both safe and effective against the bacteria that causes the disease. Valneva expects the vaccine to be available in 2025.
What is Lyme Disease?
Lyme Disease is a bacterial infection that affects more than 300,000 people in the US alone, every year. The infection is caused by the bacteria Borrelia burgdorferi, which is usually carried by deer ticks, and transferred to humans when bitten. Early symptoms include a bulls-eye rash, headache, fatigue, and a fever but can progress to attack the joints, heart, and nervous system if left untreated. Thankfully, most Lyme Disease can be treated with antibiotics but effects of the infection may still persist.
Source: Miami Herald Story